• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·INDGN.BO
Share

Indegene Limited Stocks

₹ 578.9Last Updated 10.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.53B

₹ 578.9
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Indegene Limited operates as a global commercialization partner within the life sciences sector. The company assists biopharmaceutical, nascent biotechnology, and medical device organizations throughout their product's journey, from initial development and market introduction to sustained growth and impact. Its comprehensive offerings include a range of enterprise solutions for commercial, medical, and clinical operations, advanced omnichannel activation strategies, and its proprietary NEXT technology platforms. Established in 1998, the company maintains its headquarters in Bengaluru, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of INDGN.BO is 570 and suggests 3.11% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 21:24

The owner of Vimeo has agreed to acquire Miro, a company with Russian roots, for $1.4 billion

10.09.2026 20:22

Europe's largest airline has warned of the risk of a "significant increase" in prices due to oil prices

10.09.2026 19:47

A Historic Shift: BlackRock Proposes an Alternative to the 60/40 Portfolio

10.09.2026 19:09

"A Bit of Chaos": How Sergey Brin Is Building Gemini in Startup Style in a Kitchen at Google

10.09.2026 18:40

The Nasdaq fell 1% at the start of trading in the U.S. due to a sharp rise in oil prices

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026